Can you take Dolasetron with Vobrig?

Dolasetron has a major potential interaction with Abnormal Electrocardiogram.

Dolasetron may cause acute but usually reversible and self-limiting interval changes in the electrocardiogram, including PR, QTc and JT prolongation and QRS widening. The incidence and severity of these changes are related to serum levels of the active metabolite, hydrodolasetron. Cardiovascular morbidity such as heart block and cardiac arrhythmias may occur rarely. Therapy with dolasetron should be administered cautiously in patients with or predisposed to prolongation of cardiac conduction intervals. Risk factors include hypokalemia; hypomagnesemia; use of diuretics that may induce electrolyte abnormalities; use of antiarrhythmic agents or other drugs that may cause QTc prolongation; cumulative high-dose anthracycline therapy; significant bradycardia; congestive heart failure; myocardial ischemia; and atrial fibrillation.

Dolasetron has a major potential interaction with Arrhythmia.

Dolasetron may cause acute but usually reversible and self-limiting interval changes in the electrocardiogram, including PR, QTc and JT prolongation and QRS widening. The incidence and severity of these changes are related to serum levels of the active metabolite, hydrodolasetron. Cardiovascular morbidity such as heart block and cardiac arrhythmias may occur rarely. Therapy with dolasetron should be administered cautiously in patients with or predisposed to prolongation of cardiac conduction intervals. Risk factors include hypokalemia; hypomagnesemia; use of diuretics that may induce electrolyte abnormalities; use of antiarrhythmic agents or other drugs that may cause QTc prolongation; cumulative high-dose anthracycline therapy; significant bradycardia; congestive heart failure; myocardial ischemia; and atrial fibrillation.

The leuprolide in Vobrig has a moderate potential interaction with Cardiovascular Conditions and Disorders.

Increased risk of developing myocardial infarction, sudden cardiac death and stroke has been reported in association with the use of GnRH agonists such as leuprolide, and triptorelin. Cardiovascular risk factors should be evaluated carefully before treatment initiation. Patients should be monitored for symptoms and signs suggestive of development or cardiovascular disease and should be managed according to current clinical practice.

The leuprolide in Vobrig has a moderate potential interaction with Diabetes Mellitus.

Hyperglycemia and an increased risk of developing diabetes have been reported in men receiving GnRH agonists such as leuprolide and triptorelin. Caution is advised in patients with diabetes as treatment with these agents may risk glycemic control. Monitor blood glucose and/or HbA1c periodically in patients receiving treatment.

Dolasetron has a major potential interaction with Electrolyte Abnormalities.

Dolasetron may cause acute but usually reversible and self-limiting interval changes in the electrocardiogram, including PR, QTc and JT prolongation and QRS widening. The incidence and severity of these changes are related to serum levels of the active metabolite, hydrodolasetron. Cardiovascular morbidity such as heart block and cardiac arrhythmias may occur rarely. Therapy with dolasetron should be administered cautiously in patients with or predisposed to prolongation of cardiac conduction intervals. Risk factors include hypokalemia; hypomagnesemia; use of diuretics that may induce electrolyte abnormalities; use of antiarrhythmic agents or other drugs that may cause QTc prolongation; cumulative high-dose anthracycline therapy; significant bradycardia; congestive heart failure; myocardial ischemia; and atrial fibrillation.

The leuprolide in Vobrig has a moderate potential interaction with Electrolyte Abnormalities.

Androgen deprivation therapy may prolong the QT/QTc interval. Health care providers should consider if benefits of therapy outweigh the potential risks in patients with congenital long QT syndrome, congestive heart failure, electrolyte abnormalities, or taking other drugs that can also prolong the QT interval. Consider periodic monitoring of EKG and electrolytes.

Dolasetron has a major potential interaction with Heart Failure.

Dolasetron may cause acute but usually reversible and self-limiting interval changes in the electrocardiogram, including PR, QTc and JT prolongation and QRS widening. The incidence and severity of these changes are related to serum levels of the active metabolite, hydrodolasetron. Cardiovascular morbidity such as heart block and cardiac arrhythmias may occur rarely. Therapy with dolasetron should be administered cautiously in patients with or predisposed to prolongation of cardiac conduction intervals. Risk factors include hypokalemia; hypomagnesemia; use of diuretics that may induce electrolyte abnormalities; use of antiarrhythmic agents or other drugs that may cause QTc prolongation; cumulative high-dose anthracycline therapy; significant bradycardia; congestive heart failure; myocardial ischemia; and atrial fibrillation.

The leuprolide in Vobrig has a moderate potential interaction with Heart Failure.

Androgen deprivation therapy may prolong the QT/QTc interval. Health care providers should consider if benefits of therapy outweigh the potential risks in patients with congenital long QT syndrome, congestive heart failure, electrolyte abnormalities, or taking other drugs that can also prolong the QT interval. Consider periodic monitoring of EKG and electrolytes.

Dolasetron has a major potential interaction with Hypokalemia.

Dolasetron may cause acute but usually reversible and self-limiting interval changes in the electrocardiogram, including PR, QTc and JT prolongation and QRS widening. The incidence and severity of these changes are related to serum levels of the active metabolite, hydrodolasetron. Cardiovascular morbidity such as heart block and cardiac arrhythmias may occur rarely. Therapy with dolasetron should be administered cautiously in patients with or predisposed to prolongation of cardiac conduction intervals. Risk factors include hypokalemia; hypomagnesemia; use of diuretics that may induce electrolyte abnormalities; use of antiarrhythmic agents or other drugs that may cause QTc prolongation; cumulative high-dose anthracycline therapy; significant bradycardia; congestive heart failure; myocardial ischemia; and atrial fibrillation.

Dolasetron has a major potential interaction with Ischemic Heart Disease.

Dolasetron may cause acute but usually reversible and self-limiting interval changes in the electrocardiogram, including PR, QTc and JT prolongation and QRS widening. The incidence and severity of these changes are related to serum levels of the active metabolite, hydrodolasetron. Cardiovascular morbidity such as heart block and cardiac arrhythmias may occur rarely. Therapy with dolasetron should be administered cautiously in patients with or predisposed to prolongation of cardiac conduction intervals. Risk factors include hypokalemia; hypomagnesemia; use of diuretics that may induce electrolyte abnormalities; use of antiarrhythmic agents or other drugs that may cause QTc prolongation; cumulative high-dose anthracycline therapy; significant bradycardia; congestive heart failure; myocardial ischemia; and atrial fibrillation.

The leuprolide in Vobrig has a moderate potential interaction with Long QT Syndrome.

Androgen deprivation therapy may prolong the QT/QTc interval. Health care providers should consider if benefits of therapy outweigh the potential risks in patients with congenital long QT syndrome, congestive heart failure, electrolyte abnormalities, or taking other drugs that can also prolong the QT interval. Consider periodic monitoring of EKG and electrolytes.

Dolasetron has a major potential interaction with Magnesium Imbalance.

Dolasetron may cause acute but usually reversible and self-limiting interval changes in the electrocardiogram, including PR, QTc and JT prolongation and QRS widening. The incidence and severity of these changes are related to serum levels of the active metabolite, hydrodolasetron. Cardiovascular morbidity such as heart block and cardiac arrhythmias may occur rarely. Therapy with dolasetron should be administered cautiously in patients with or predisposed to prolongation of cardiac conduction intervals. Risk factors include hypokalemia; hypomagnesemia; use of diuretics that may induce electrolyte abnormalities; use of antiarrhythmic agents or other drugs that may cause QTc prolongation; cumulative high-dose anthracycline therapy; significant bradycardia; congestive heart failure; myocardial ischemia; and atrial fibrillation.

The leuprolide in Vobrig has a moderate potential interaction with Osteoporosis.

Decreased bone density has been reported in men who have had orchiectomy or who have been treated with a GnRH agonist analog as leuprolide. It can be anticipated that long periods of medical castration in men will have effects on bone density. Bone density loss may not be reversible. Therapy with leuprolide should be administered cautiously in patients with major risk factors for decreased bone mineral content, such as chronic alcohol and/or tobacco use, a strong family history of osteoporosis, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants, corticosteroids). Therapy beyond six months with gonadotropin-releasing hormone analogs is not recommended for patients with major risk factors for decreased bone mineral content.

The leuprolide in Vobrig has a moderate potential interaction with Seizures.

Convulsions have been observed in patients taking leuprolide, including patients who have a history of seizures, epilepsy, or brain disorders, and in those taking medications associated with convulsions. Convulsions have also been reported in patients without any of these conditions. Caution is advised in patients with a history of seizures.